Clinical Scorecard: Axpaxli Could Transform Wet AMD Care
At a Glance
| Category | Detail |
|---|---|
| Condition | Neovascular (wet) age-related macular degeneration (nAMD) |
| Key Mechanisms | Axitinib, a tyrosine kinase inhibitor (TKI) with antiangiogenic activity, delivered via a bioresorbable intravitreal hydrogel. |
| Target Population | Patients with neovascular age-related macular degeneration. |
| Care Setting | Ophthalmology clinics and practices. |
Key Highlights
- Axpaxli outperformed FDA-approved anti-VEGF therapy in the phase 3 SOL-1 trial.
- Two-thirds of patients were rescue-free at week 52 with a single injection.
- The drug demonstrated stable OCT measurements up to 30 µm at week 36.
- This study represents the first superiority trial to succeed in wet AMD treatment.
- FDA guidelines were strictly followed, leading to a special protocol agreement (SPA).
Guideline-Based Recommendations
Diagnosis
- Utilize OCT for objective measurement of disease control.
Management
- Consider Axpaxli as a treatment option for nAMD based on SOL-1 trial results.
Monitoring & Follow-up
- Regular OCT assessments to monitor disease progression and treatment efficacy.
Risks
- Monitor for potential adverse effects associated with TKI therapy.
Patient & Prescribing Data
Patients diagnosed with neovascular age-related macular degeneration.
Axpaxli may provide a more sustainable treatment option with fewer injections required.
Clinical Best Practices
- Follow FDA guidelines for clinical trial design and reporting.
- Utilize both subjective (visual acuity) and objective (OCT) measures for assessing treatment outcomes.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
